NNOX:NASDAQNANO-X IMAGING LTD Analysis
Data as of 2026-05-26 - not real-time
$1.84
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Nano‑X is trading at $1.84, well below its 20‑day SMA of $1.77, 50‑day SMA of $2.11 and 200‑day SMA of $3.09, indicating a deep‑seated bearish price environment. The RSI sits at 47, suggesting neutral momentum, while the MACD shows a modest bullish histogram (+0.04) but the line remains negative, reinforcing a cautious outlook. Volatility is extreme at >114% over the past 30 days and beta is 1.72, amplifying price swings, and the stock has suffered a historic drawdown of over 71%. Valuation metrics point to a potential bargain: price‑to‑book is 0.92, upside/downside is quoted at +291%, and the Fear‑Greed Index reads “Extreme Greed,” hinting at speculative enthusiasm despite weak fundamentals.
Fundamentally, the company posts a negative gross margin (‑98%) and operating margin (‑4.8%), with no earnings and a trailing EPS of –1.16, yet it holds $59.6 M in cash against $7.85 M of debt, providing a modest runway. Recent news highlights a string of U.S. distribution agreements that could seed commercial traction, but multiple securities‑fraud investigations by law firms add a significant legal cloud. The analyst consensus is a “strong buy,” but only three analysts contribute, underscoring limited coverage.
Fundamentally, the company posts a negative gross margin (‑98%) and operating margin (‑4.8%), with no earnings and a trailing EPS of –1.16, yet it holds $59.6 M in cash against $7.85 M of debt, providing a modest runway. Recent news highlights a string of U.S. distribution agreements that could seed commercial traction, but multiple securities‑fraud investigations by law firms add a significant legal cloud. The analyst consensus is a “strong buy,” but only three analysts contribute, underscoring limited coverage.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price below all major moving averages
- ongoing securities‑fraud investigations
- decreasing volume and high volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- new multi‑year distribution and deployment agreements
- substantial cash buffer relative to debt
- significant upside potential relative to book value
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- large addressable market for AI‑enabled imaging
- potential FDA clearances and broader regulatory approvals
- strategic positioning in teleradiology and cloud‑based services
Key Metrics & Analysis
Financial Health
Revenue Growth24.00%
P/E Ratio-9.2
ROE-45.62%
ROA-20.37%
Debt/Equity5.62
P/B Ratio0.9
Op. Cash Flow$-40793000
Free Cash Flow$-25294250
Industry P/E27.6
Technical Analysis
TrendBearish
RSI47.2
Support$1.59
Resistance$1.97
MA 20$1.77
MA 50$2.11
MA 200$3.09
MACDBullish
VolumeDecreasing
Fear & Greed Index91.63
Valuation
Target Price$7.20
Upside/Downside291.30%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.72
Volatility114.51%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.